Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Drug Development
420 Articles Available
1
18
Can't find what you're looking for? Try our
advanced search
.
Endpoint
Array Biopharma Announces Braftovi + Mektovi + Cetuximab Meet Primary Endpoints in Metastatic Colorectal Cancer
PR-M05-19-NI-069
Endpoints
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, Has Been Met, Confirming Previously Published Activity
PR-M05-19-NI-065
Clinical Data
New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol
PR-M05-19-NI-064
Drug Design
Janssen, Iktos Collaborate on In Silico Drug Design
PAO-M05-19-NI-022
Funding
Philogen Raises $70 Million
PAO-M05-19-NI-019
Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis
PR-M05-19-NI-055
Generics
Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States
PR-M05-19-NI-045
Cell and Gene Therapy
Semma Therapeutics Announces Publication in Nature Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes
PR-M05-19-NI-039
Vaccines
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
PR-M05-19-NI-041
Drug Approval
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
PR-M05-19-NI-036
FDA
The FDA Changes the Drug Approval Process
PAO-M05-19-NI-014
Asthma
GSK Has Hopes for Trelegy in Asthma
PAO-M05-19-NI-011
Partnership
Alector Opts for Lonza’s Ibex™ Develop to Secure Future Manufacturing for Neurodegeneration Therapies
PR-M05-19-NI-032
Drug Development
Arrakis Therapeutics Developing Oral Drugs that Target RNA
PAO-M05-19-NI-008
Drug Development
Lung Cancer Drug Demonstrates Improved Survival in Animal Models
PAO-M05-19-NI-003
Research
Mayo Clinic Researchers Say Fecal Transplants Show Promise for Treating Antibiotic-Resistant Bacteria
PR-M05-19-NI-002
Drug Development
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cance
PR-M05-19-NI-001
Appointment
Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives
PR-M05-19-NI-009
Series C Financing
Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics for Treatment of Cancer and Fibrotic Diseases
PR-M04-19-NI-091
Trial Update
Merck Provides Update on Phase 3 KEYNOTE-062 Trial
PR-M04-19-NI-085
FDA Approval
FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults
PR-M04-19-NI-082
Clinical Development
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache
PR-M04-19-NI-077
Market Prediction
IQVIA Institute for Human Data Science Study: Record 59 New U.S. Drugs Launched in 2018, Success Rates Fall, R&D Trends Could Improve Productivity by 2023
PR-M04-19-NI-075
Generics
Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
PR-M04-19-NI-072
1
18
»
